Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
mechanism:
5-HT2A agonist (26) ·
Monoamine releasing agent (9) ·
GABAA positive allosteric modulator (8) ·
CB1/CB2 agonist (7) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Potent 5-HT2A agonist (5) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
NMDA antagonist (3) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist; sigma receptor agonist (2) ·
Prodrug of GHB (2)
None (140) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000040-QINU`"' (1) ·
'"`UNIQ--vote-00000669-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)
None (140) ·
10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) ·
10 mg ~1 h before sexual activity (1) ·
100 mg ~15 min before sexual activity (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
None (140) ·
2.5, 5, 10, 20 mg tabs (1) ·
2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) ·
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
50, 100, 200 mg tabs (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
None (140) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Avoid; may cause fetal harm (1) ·
Category B (3) ·
Category C (not relevant; not used in women) (1)
Showing below up to 156 results in range #1 to #156.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOMe
- 25N-NBOMe
- 2C-B-FLY
- 2C-C
- 2C-D
- 2C-E
- 2C-I
- 2C-P
- 2C-T-2
- 2C-T-7
3
- 3,4-CTMP
- 3-FA
- 3-FMA
- 3-HO-PCE
- 3-HO-PCE
- 3-HO-PCP
- 3-HO-PCP
- 3-MeO-PCE
- 3-MeO-PCE
- 3-MeO-PCP
- 3-MeO-PCP
- 3-MMC
4
5
A
B
C
D
- Deschloroetizolam
- Deschloroketamine
- Deschloroketamine
- DET
- Dextromethorphan
- Dextrorphan
- Diclazepam
- Diphenidine
- DiPT
- DOB
- DOC
- DOI
- DOM
- DPT
E
- Ephenidine
- Ephylone
- EPT
- Escaline
- Esketamine
- ETH-LAD
- Ethcathinone
- Ethylone
- Ethylphenidate
- Eticyclidine
- Eticyclidine
- Etizolam
F
G
H
I
J
L
M
- MCPP
- MDPV
- Mephedrone
- MET
- Methallylescaline
- Methcathinone
- Methoxetamine
- Methoxetamine
- Methylnaphthidate
- Methylone
- Metizolam
- Mexedrone
- MiPLA
- MiPT


